| 1 |
Murlykina MV, Kolomiets OV, Kornet MM, Sakhno YI, Desenko SM, Dyakonenko VV, Shishkina SV, Brazhko OA, Musatov VI, Tsygankov AV, Van der Eycken EV, Chebanov VA. Doebner-type pyrazolopyridine carboxylic acids in an Ugi four-component reaction. Beilstein J Org Chem 2019;15:1281-8. [PMID: 31293676 DOI: 10.3762/bjoc.15.126] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 2 |
Ganesan A, Barakat K. Applications of computer-aided approaches in the development of hepatitis C antiviral agents. Expert Opin Drug Discov 2017;12:407-25. [PMID: 28164720 DOI: 10.1080/17460441.2017.1291628] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 6.2] [Reference Citation Analysis]
|
| 3 |
Vidotto A, Morais AT, Ribeiro MR, Pacca CC, Terzian AC, Gil LH, Mohana-Borges R, Gallay P, Nogueira ML. Systems Biology Reveals NS4B-Cyclophilin A Interaction: A New Target to Inhibit YFV Replication. J Proteome Res 2017;16:1542-55. [PMID: 28317380 DOI: 10.1021/acs.jproteome.6b00933] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 4 |
Han J, Kyu Lee M, Jang Y, Cho WJ, Kim M. Repurposing of cyclophilin A inhibitors as broad-spectrum antiviral agents. Drug Discov Today 2022:S1359-6446(22)00207-0. [PMID: 35609743 DOI: 10.1016/j.drudis.2022.05.016] [Reference Citation Analysis]
|
| 5 |
Han J, Lee HW, Jin Y, Khadka DB, Yang S, Li X, Kim M, Cho WJ. Molecular design, synthesis, and biological evaluation of bisamide derivatives as cyclophilin A inhibitors for HCV treatment. Eur J Med Chem 2020;188:112031. [PMID: 31923861 DOI: 10.1016/j.ejmech.2019.112031] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 6 |
Liu CW, Atkinson MA, Zhang Q. Type 1 diabetes cadaveric human pancreata exhibit a unique exocrine tissue proteomic profile. Proteomics 2016;16:1432-46. [PMID: 26935967 DOI: 10.1002/pmic.201500333] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 3.3] [Reference Citation Analysis]
|
| 7 |
Ahmed-Belkacem A, Colliandre L, Ahnou N, Nevers Q, Gelin M, Bessin Y, Brillet R, Cala O, Douguet D, Bourguet W, Krimm I, Pawlotsky JM, Guichou JF. Fragment-based discovery of a new family of non-peptidic small-molecule cyclophilin inhibitors with potent antiviral activities. Nat Commun 2016;7:12777. [PMID: 27652979 DOI: 10.1038/ncomms12777] [Cited by in Crossref: 41] [Cited by in F6Publishing: 33] [Article Influence: 6.8] [Reference Citation Analysis]
|
| 8 |
Li G, De Clercq E. Current therapy for chronic hepatitis C: The role of direct-acting antivirals. Antiviral Res. 2017;142:83-122. [PMID: 28238877 DOI: 10.1016/j.antiviral.2017.02.014] [Cited by in Crossref: 93] [Cited by in F6Publishing: 83] [Article Influence: 18.6] [Reference Citation Analysis]
|
| 9 |
Li X, Han J, Lee HW, Yoon YS, Jin Y, Khadka DB, Yang S, Kim M, Cho WJ. SAR study of bisamides as cyclophilin a inhibitors for the development of host-targeting therapy for hepatitis C virus infection. Bioorg Med Chem 2020;28:115679. [PMID: 32912430 DOI: 10.1016/j.bmc.2020.115679] [Reference Citation Analysis]
|
| 10 |
Jin G, Lee J, Lee K. Chemical genetics-based development of small molecules targeting hepatitis C virus. Arch Pharm Res 2017;40:1021-36. [PMID: 28856597 DOI: 10.1007/s12272-017-0949-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
|
